Discontinued — last reported Q4 '25
Business Segments · Intangible asset impairments
Biopharma — Intangible asset impairments
Pfizer Biopharma — Intangible asset impairments increased by 1300.0% to $3.64B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 25.5%, from $2.90B to $3.64B. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
StatementSegment
CategoryRisk
SignalLower is better
VolatilityVolatile
First reportedQ1 2018
Last reportedQ4 2025Feb 26, 2026
Rolls up toImpairment Charges
How to read this metric
An increase signals that previously acquired assets are underperforming or facing competitive/regulatory headwinds.
Detailed definition
Non-cash charges recognized when the carrying value of intangible assets, such as acquired patents or drug licenses, exc...
Peer comparison
Commonly reported as 'Impairment of Intangible Assets' across the pharmaceutical industry following M&A activity.
Metric ID:
pfe_segment_biopharma_intangible_asset_impairmentsHistorical Data
12 periods
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q4 '23 | Q2 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $50.00M | $50.00M | $50.00M | $50.00M | $128.00M | $2.80B | $240.00M | $2.90B | $210.00M | $0.00 | $260.00M | $3.64B |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +156.0% | >999% | -91.4% | >999% | -92.8% | -100.0% | — | >999% |
| YoY Change | — | — | — | — | +156.0% | >999% | — | +3.6% | — | -100.0% | — | +25.5% |
Range$0.00 – $3.64B
CAGR+375.5%
Avg YoY Growth>999%
Median YoY Growth+25.5%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Pfizer's biopharma — intangible asset impairments?
- Pfizer (PFE) reported biopharma — intangible asset impairments of $3.64B in Q4 2025.
- How has Pfizer's biopharma — intangible asset impairments changed year-over-year?
- Pfizer's biopharma — intangible asset impairments increased by 25.5% year-over-year, from $2.90B to $3.64B.
- What does biopharma — intangible asset impairments mean?
- The reduction in the recorded value of intangible assets like patents or licenses due to diminished expected future benefits.